Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ResMed (NYSE: RMD), a provider of medical products that treat respiratory disorders and sleep-disordered breathing, are no snooze today, shooting up 13% at one point following better-than-expected second-quarter earnings results.

So what: It was actually a fairly mixed quarter for ResMed, but shareholders seem pleased given that the company was able to surpass Wall Street's expectation of a $0.38 profit and deliver $0.42 in earnings to shareholders. On the other hand, sales actually fell short of consensus figures of $339.6 million, coming in at $332.7 million. Gross margin also contracted by 110 basis points during the quarter to 59.7%.

Now what: That last bit of info is what has me disturbed. Expenses rose by 11.7% during the quarter and the company is actually forecasting margins will range from 58% to 60% in 2012 -- so if anything, they have a better chance of shrinking from this most recent quarter. At 17 times forward earnings, ResMed appears fairly valued and unless it can significantly reduce expenses or grow its margin, I see plenty of other more enticing opportunities in the medical products sector.

Craving more input? Start by adding ResMed to your free and personalized watchlist so you can keep track of the latest news with the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.